Please read more at the following links:
National Geographic (subscription required)
Paper published in Proceedings of the National Academy of Sciences (PNAS). We discover further metabolic disturbances that contribute to glaucoma vulnerability. We expand the treatment options by showing that both pyruvate or rapamycin are protective against glaucoma. This builds on our concept of metabolic and resilience boosting treatments.
Further work from the John lab demonstrating that metabolism supporting, Resilence-based treatments are effectice against glaucoma. We that treatment with vitamin B3 enhances the effects of gene-based therapeutic interventions and protects from all assessed measures of glaucoma.
Paper published in Proceedings of the National Academy of Sciences (PNAS) suggests that immune changes occur very early following IOP elevation and prior to any detected retinal ganglion cell dysfunction. The research provides evidence that astrocytes protect retinal ganglion cells during periods of increased pressure in the eye via a pathway involving complement C3.
A breakthrough paper demonstrating metabolic abnormalities in glaucoma. We show that NAD boosting treatments, including gene therapy, are potently protective in an inherited mouse model of glaucoma. This work led to the concept of Resilience-boosting treatments that enhance bioenergetic and other cellular resources to prevent glaucoma.